Table 1 Drug efficacy and potency in 10 breast cell lines interpreted by IC50, AUC, GR50, and GRmax values.

From: Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

 

Drug

 

Bortezomib

Carboplatin

Carfilzomib

Celastrol

Cisplatin

Delanzomib

Docetaxel

Doxorubicin

Epirubicin

Epoxomicin

MG 132

MLN 2238

MLN 9708

Nedaplatin

Oprozomib

Paclitaxel

PI-1840

VR-23

IC50 (µM)

BT-549

NA

NA

4.4

1.3

0.053

NA

NA

7.6

4.6

NA

4.3

NA

NA

0.15

NA

NA

NA

NA

CAL-148

NA

0.93

NA

3.7

0.048

NA

NA

0.22

0.20

NA

NA

NA

NA

0.32

NA

NA

NA

NA

HCC1806

0.79

NA

1.7

2.1

0.048

NA

NA

NA

NA

0.47

3.1

3

NA

0.15

6

NA

NA

NA

HCC38

0.024

0.89

0.57

1.4

0.030

0.012

NA

2.9

2.3

0.054

0.57

0.11

0.13

0.093

0.68

7.1

NA

NA

HCC70

0.81

0.45

2.1

1.8

0.022

3.3

NA

3.3

1.6

0.98

3.7

2.7

4.8

0.046

7.6

NA

NA

NA

MDA-MB-436

NA

NA

NA

3.2

0.064

NA

NA

9.7

NA

NA

NA

NA

NA

0.23

NA

NA

NA

NA

MDA-MB-453

NA

NA

NA

3.7

0.24

NA

NA

8.1

5.3

NA

NA

4.3

NA

NA

NA

NA

NA

NA

MDA-MB-468

0.054

0.47

0.46

1.0

0.015

0.077

NA

3.0

2.2

0.11

1.4

0.24

0.80

0.067

3.2

NA

NA

NA

MCF-10A

0.046

0.73

0.54

1.6

0.027

0.018

0.050

0.99

0.69

0.088

0.94

0.41

0.38

0.075

2.0

0.86

NA

NA

MCF-7

NA

NA

NA

2.8

0.16

NA

NA

1.8

1.5

1.2

NA

NA

NA

NA

NA

NA

NA

6.0

AUC

BT-549

0.66

0.85

0.67

0.82

0.57

0.73

0.79

0.89

0.88

0.73

0.83

0.75

0.80

0.66

0.81

0.87

0.99

0.98

CAL-148

0.77

0.92

0.84

0.85

0.48

0.77

0.89

0.72

0.73

0.78

0.89

0.83

0.88

0.78

0.90

0.92

1.0

1.0

HCC1806

0.70

0.90

0.73

0.81

0.48

0.74

0.64

0.87

0.86

0.73

0.82

0.75

0.79

0.66

0.85

0.72

1.0

1.0

HCC38

0.40

0.88

0.71

0.79

0.45

0.42

0.78

0.83

0.81

0.47

0.71

0.59

0.59

0.62

0.73

0.81

1.0

1.0

HCC70

0.68

0.83

0.76

0.82

0.37

0.75

0.83

0.88

0.83

0.72

0.87

0.78

0.82

0.50

0.89

0.86

1.0

0.98

MDA-MB-436

0.75

0.91

0.73

0.85

0.62

0.79

0.69

0.85

0.84

0.77

0.86

0.88

0.86

0.76

0.84

0.78

1.0

1.0

MDA-MB-453

0.75

0.98

0.77

0.87

0.75

0.76

0.87

0.88

0.90

0.70

0.87

0.81

0.88

0.86

0.84

0.93

1.0

0.99

MDA-MB-468

0.57

0.81

0.65

0.75

0.37

0.58

0.77

0.84

0.80

0.65

0.81

0.67

0.72

0.61

0.76

0.81

0.98

0.97

MCF-10A

0.59

0.90

0.66

0.81

0.42

0.62

0.63

0.72

0.69

0.58

0.78

0.72

0.72

0.57

0.79

0.73

1.0

1.0

MCF-7

0.78

0.91

0.81

0.89

0.66

0.77

0.75

0.93

0.89

0.74

0.87

0.87

0.87

0.82

0.88

0.79

1.0

0.98

GR50 (µM)

BT-549

0.10

0.67

1.0

1.5

0.035

NA

NA

5.6

4.3

0.13

1.4

0.14

0.84

0.081

0.94

NA

NA

NA

CAL-148

0.12

0.49

0.37

3.1

0.032

0.023

NA

0.12

0.11

0.77

3.4

0.27

0.50

0.21

1.1

1.1

NA

NA

HCC1806

0.38

NA

0.95

3.4

0.042

NA

NA

6.0

6.2

0.29

2.5

3.3

4.3

0.12

6.0

0.84

NA

NA

HCC38

0.010

0.43

0.38

1.2

0.019

0.0082

0.013

0.77

0.69

0.044

0.37

0.071

0.069

0.054

0.33

0.11

NA

NA

HCC70

0.10

0.27

0.48

1.2

0.015

0.37

NA

1.8

1.0

0.14

2.1

0.74

1.2

0.30

3.7

0.38

NA

NA

MDA-MB-436

0.021

0.87

0.0018

2.4

0.043

0.029

0.0050

3.4

3.6

0.32

0.29

0.16

0.11

0.13

0.075

0.055

NA

NA

MDA-MB-453

0.063

NA

0.22

3.4

0.095

0.027

NA

4.6

3.2

0.015

1.7

0.64

1.8

0.41

3.5

NA

NA

9319.49

MDA-MB-468

0.017

0.24

0.11

0.75

0.0075

0.011

NA

1.5

0.96

0.051

0.61

0.055

0.10

40.46

0.39

1.4

NA

NA

MCF-10A

0.012

0.76

0.11

1.8

0.028

0.012

0.0090

0.98

0.69

0.095

0.40

0.076

0.070

0.074

0.36

0.098

NA

NA

MCF-7

0.031

0.36

0.19

3.3

0.015

0.037

0.0065

5.7

1.1

0.075

0.57

0.34

0.27

0.075

0.27

0.041

NA

6334.47

GRmax

BT-549

0.39

0.39

0.37

−0.51

−0.16

0.48

0.61

0.36

0.34

0.38

0.26

0.40

0.43

−0.02

0.38

0.58

1.0

0.85

CAL-148

0.17

0.03

−0.01

−0.84

−0.97

0.39

0.74

0.15

0.14

0.11

0.22

0.18

0.40

−0.93

0.14

0.51

1.0

0.95

HCC1806

0.33

0.53

0.31

−0.82

−0.72

0.50

0.56

0.54

0.45

0.34

0.31

0.39

0.47

−0.38

0.42

0.51

0.98

0.93

HCC38

−0.99

0.03

−0.99

−0.96

−0.67

−0.97

0.17

0.01

−0.03

−0.74

−0.98

−0.99

−0.99

−0.58

−0.98

−0.50

1.0

0.95

HCC70

−0.55

−0.42

−0.57

−0.98

−0.89

−0.36

0.72

−0.35

−0.49

−0.52

−0.40

−0.36

−0.34

−0.83

−0.10

0.46

1.0

0.82

MDA-MB-436

−0.76

0.41

−0.89

−0.63

0.17

−0.84

−0.81

0.26

0.26

0.37

−0.88

−0.78

−0.82

0.22

−0.93

−0.97

1.0

1.0

MDA-MB-453

0.40

0.79

0.41

−0.83

0.25

0.31

0.74

0.21

0.20

0.32

0.43

0.32

0.39

0.34

0.43

0.71

0.93

0.40

MDA-MB-468

0

0.02

0.05

−0.61

−0.46

0.09

0.64

0.06

−0.02

0.01

0.07

0.01

0.07

−0.38

0.12

0.32

0.96

0.74

MCF-10A

−0.41

0.19

−0.36

−0.65

−0.32

−0.10

0.16

0.02

0.01

−0.05

−0.36

−0.21

−0.26

−0.40

−0.06

−0.19

1.0

1.0

MCF-7

−0.43

−0.15

−0.45

−0.30

−0.96

−0.28

−0.44

0.44

0.42

0.42

−0.32

−0.29

−0.48

−0.57

−0.45

−0.56

0.97

0.82

  1. Note: NA denotes IC50 and GR50 values (calculated using the GRmetrics package) that were removed for cases where values were (a) not reached (INF) or (b) higher than the tested drug dose range.